The issue with authorizing on data generated in Europe is not quite true. It's a whole package of data, which I tried to express. The data from Europe was really on the efficacy of the H1N1; that was the early data coming in. The safety package was primarily from the H5N1, which has been tested in Europe and the United States and in Canada as well.
So the data are coming in, to start with from Europe, but there are data from Canada. There are safety data coming in from Canada as well. It's the same vaccine. So you cannot wait to get the data from Canada as well; you already have the data from European studies.
I think that's what you're asking.